Published in Growth Factors on December 01, 2007
Endoplasmic reticulum stress drives proteinuria-induced kidney lesions via Lipocalin 2. Nat Commun (2016) 1.50
Intestinal hormones and growth factors: effects on the small intestine. World J Gastroenterol (2009) 0.98
Expression of TRPC6 in benign and malignant human prostate tissues. Asian J Androl (2009) 0.86
Evidence of K+ channel function in epithelial cell migration, proliferation, and repair. Am J Physiol Cell Physiol (2013) 0.83
The role of TRPC6 in HGF-induced cell proliferation of human prostate cancer DU145 and PC3 cells. Asian J Androl (2010) 0.83
Complementary roles of KCa3.1 channels and β1-integrin during alveolar epithelial repair. Respir Res (2015) 0.81
Canonical Transient Receptor Potential 6 Channel: A New Target of Reactive Oxygen Species in Renal Physiology and Pathology. Antioxid Redox Signal (2016) 0.76
TRPC6 May Protect Renal Ischemia-Reperfusion Injury Through Inhibiting Necroptosis of Renal Tubular Epithelial Cells. Med Sci Monit (2016) 0.75
Control of cell mechanics by RhoA and calcium fluxes during epithelial scattering. Tissue Barriers (2016) 0.75
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
Oct-4 expression in adult human differentiated cells challenges its role as a pure stem cell marker. Stem Cells (2007) 2.39
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res (2003) 2.14
Image in clinical medicine. Hypercarotenemia. N Engl J Med (2002) 2.03
Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact. Cancer Treat Rev (2011) 1.63
The syndrome of inappropriate antidiuresis: pathophysiology, clinical management and new therapeutic options. Nephron Clin Pract (2011) 1.61
Saquinavir in steroid-dependent and -resistant nephrotic syndrome: a pilot study. Nephrol Dial Transplant (2012) 1.51
Hepatocyte growth factor (HGF) modulates matrix turnover in human glomeruli. Kidney Int (2005) 1.44
Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle (2012) 1.44
Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Nephrol Dial Transplant (2007) 1.43
Questioning the oncogenic role of DeltaNp73alpha in different cell lines expressing p53 or not. Cancer Biol Ther (2006) 1.43
PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res (2005) 1.43
Severe symptomatic hyponatremia during sibutramine therapy: a case report. Am J Kidney Dis (2008) 1.39
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res (2005) 1.38
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2011) 1.30
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene (2004) 1.28
Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53. Nucleic Acids Res (2007) 1.23
Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle (2004) 1.22
Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther (2011) 1.18
Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer (2010) 1.16
Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res (2011) 1.16
Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res (2008) 1.14
Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter. Clin Cancer Res (2013) 1.12
To target or not to target, that is the question. J Clin Oncol (2013) 1.12
Oxidative stress and inflammation: Implications in uremia and hemodialysis. Clin Biochem (2011) 1.04
Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells. Mol Cancer Ther (2011) 1.03
Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sites. Cell Cycle (2003) 1.03
Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin Cancer Res (2008) 1.02
Renal function and functional reserve in healthy elderly individuals. J Nephrol (2007) 1.02
Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res (2008) 1.00
Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res (2005) 1.00
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Mol Cancer Ther (2005) 0.98
Unique features of the mode of action of ET-743. Oncologist (2002) 0.97
Inhibition of Sp1-dependent transcription and antitumor activity of the new aureolic acid analogues mithramycin SDK and SK in human ovarian cancer xenografts. Gynecol Oncol (2010) 0.97
Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy. Kidney Int (2008) 0.97
Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle (2012) 0.94
p73: a chiaroscuro gene in cancer. Eur J Cancer (2007) 0.94
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer (2007) 0.94
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. Int J Biol Markers (2009) 0.93
Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors. Clin Cancer Res (2010) 0.93
Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents. Cell Cycle (2004) 0.92
Vitamin E-loaded dialyzer resets PBMC-operated cytokine network in dialysis patients. Kidney Int (2004) 0.92
Detection of a morphogenetically novel Sarcocystis hominis-like in the context of a prevalence study in semi-intensively bred cattle in Italy. Parasitol Res (2011) 0.91
Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics. Nephrol Dial Transplant (2013) 0.90
MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. Clin Cancer Res (2013) 0.90
DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1. Nucleic Acids Res (2003) 0.90
Prevention of dialysis hypotension episodes using fuzzy logic control system. Nephrol Dial Transplant (2007) 0.89
Fibrin glue instillation under skin flaps to prevent seroma-related morbidity following breast and axillary surgery. Cochrane Database Syst Rev (2013) 0.88
Across the universe of K-RAS mutations in non-small-cell-lung cancer. Curr Pharm Des (2014) 0.86
Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res (2002) 0.86
The role of fibrin glue instillation under skin flaps in the prevention of seroma formation and related morbidities following breast and axillary surgery for breast cancer: a meta-analysis. J Surg Oncol (2012) 0.86
Brostallicin: a new concept in minor groove DNA binder development. Anticancer Drugs (2004) 0.86
The role of therapeutic drug monitoring in the treatment of cytomegalovirus disease in kidney transplantation. Int Urol Nephrol (2012) 0.85
Glutathione influences c-Myc-induced apoptosis in M14 human melanoma cells. J Biol Chem (2002) 0.85
Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners. J Med Chem (2004) 0.85
Functional changes in the aging kidney. J Nephrol (2010) 0.85
Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1. Int J Cancer (2014) 0.84
In vivo evaluation of the role of DNp73alpha protein in regulating the p53-dependent apoptotic pathway after treatment with cytotoxic drugs. Int J Cancer (2007) 0.84
Revisiting ovarian cancer preclinical models: implications for a better management of the disease. Cancer Treat Rev (2013) 0.84
The antifibrogenic effect of hepatocyte growth factor (HGF) on renal tubular (HK-2) cells is dependent on cell growth. Growth Factors (2009) 0.84
Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation (2009) 0.83
Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin. Epigenetics (2013) 0.83
Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. Mol Cancer (2010) 0.83
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. Am J Cancer Res (2012) 0.83
Macrophage-stimulating protein is produced by tubular cells and activates mesangial cells. J Am Soc Nephrol (2002) 0.83
ALDH enzymatic activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am J Cancer Res (2013) 0.83
Dialysis treatment and regulatory T cells. Nephrol Dial Transplant (2010) 0.82
Glomerular filtration rate: utility for assessing long-term renal allograft outcomes in kidney allograft recipients. J Nephrol (2013) 0.81
The Ron proto-oncogene product is a phenotypic marker of renal oncocytoma. Am J Surg Pathol (2003) 0.81
Serum depletion of holo-ceruloplasmin induced by silver ions in vivo reduces uptake of cisplatin. J Inorg Biochem (2012) 0.81
Hyperpigmented Paget's disease of the nipple - a diagnostic dilemma. JRSM Short Rep (2012) 0.81
Improving the selectivity of cancer treatments by interfering with cell response pathways. Eur J Cancer (2004) 0.81
Risk factors for chronic renal dysfunction in lung transplant recipients. Transplantation (2007) 0.81
Role of glutathione transferases in the mechanism of brostallicin activation. Biochemistry (2010) 0.81
GM-CSF contributes to prompt healing of ecthyma gangrenosum lesions in kidney transplant recipient. J Nephrol (2012) 0.81
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model. PLoS One (2013) 0.80
Mesenchymal stromal cells improve renal injury in anti-Thy 1 nephritis by modulating inflammatory cytokines and scatter factors. Clin Sci (Lond) (2011) 0.80
Henle loop basement membrane as initial site for Randall plaque formation. Am J Kidney Dis (2006) 0.80
Direct but not indirect co-culture with osteogenically differentiated human bone marrow stromal cells increases RANKL/OPG ratio in human breast cancer cells generating bone metastases. Mol Cancer (2014) 0.80
Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone. Cancer Chemother Pharmacol (2005) 0.80
Hepatocyte growth factor and its receptor Met are induced in crescentic glomerulonephritis. Nephrol Dial Transplant (2005) 0.80